Skip to main content

Table 4 Odds ratios for postmenopausal breast cancer by genotypes in the vitamin D receptor gene according to ER and PR status of the tumour

From: Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk

Genotype

 

ER-positive tumours

ER-negative tumours

PR-positive tumours

PR-negative tumours

 

n (controls)

n (cases)

OR (95% CI)

n (cases)

OR (95% CI)

n (cases)

OR (95% CI)

n (cases)

OR (95% CI)

TaqI

         

   TT

980

337

1

121

1

297

1

159

1

   Tt/tt

1,629

653

1.18 (1.00–1.38)

186

0.88 (0.69–1.13)

547

1.10 (0.93–1.30)

293

1.11 (0.89–1.37)

FokI

         

   FF

998

394

1

127

1

331

1

190

1

   Ff/ff

1,598

586

0.95 (0.81–1.10)

177

0.86 (0.67–1.10)

505

0.96 (0.82–1.14)

257

0.84 (0.68–1.03)

VDR-5132

         

   CC

892

347

1

113

1

298

1

162

1

   CT/TT

1,715

640

0.99 (0.84–1.16)

194

0.92 (0.71–1.18)

543

0.97 (0.82–1.15)

290

0.97 (0.78–1.20)

Cdx2

         

   GG

1,701

641

1

190

1

546

1

283

1

   GA/AA

905

351

1.01 (0.86–1.17)

118

1.14 (0.88–1.46)

301

1.01 (0.86–1.20)

169

1.11 (0.90–1.38)

  1. We conducted a conditional logistic regression stratified by year of birth adjusted for age at menopause, first-degree family history of breast cancer, history of benign breast disease, number of pregnancies (≥28th week), age at menarche, breastfeeding history, total number of mammograms, use of hormone therapy, body mass index, education level and smoking status. Data on oestrogen receptor (ER) and progesterone receptor (PR) status was available for 1,302 and 1,301 cases, respectively.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us